Zimmer Biomet (NYSE:ZBH) Price Target Cut to $101.00 by Analysts at BMO Capital Markets

Zimmer Biomet (NYSE:ZBH – Get Free Report) had its price target decreased by research analysts at BMO Capital Markets from $102.00 to $101.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has a “market perform” rating on the medical equipment provider’s stock. BMO Capital Markets‘s price target points to a potential downside of 0.20% from the stock’s previous close.

ZBH has been the subject of a number of other research reports. Royal Bank Of Canada lifted their price target on Zimmer Biomet from $110.00 to $125.00 and gave the stock an “outperform” rating in a research report on Thursday, November 5th. Sanford C. Bernstein increased their price objective on Zimmer Biomet from $93.00 to $107.00 and gave the company a “market perform” rating in a report on Thursday, November 5th. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research note on Thursday, August 6th. UBS Group upped their target price on Zimmer Biomet from $120.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Finally, Citigroup upped their target price on Zimmer Biomet from $99.00 to $117.00 and gave the company a “neutral” rating in a research report on Thursday, November 5th. Seven analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $113.79.

Read Our Latest Stock Report on Zimmer Biomet

Zimmer Biomet Stock Down 1.9%

Shares of NYSE:ZBH traded down $2.01 on Monday, reaching $101.20. The company had a trading volume of 1,139,404 shares, compared to its average volume of 2,256,248. The firm has a market capitalization of $19.15 billion, a PE ratio of 25.69, a PEG ratio of 2.42 and a beta of 0.50. The company has a current ratio of 1.46, a quick ratio of 0.79 and a debt-to-equity ratio of 0.49. Zimmer Biomet has a 52-week low of $79.12 and a 52-week high of $112.54. The firm’s 50 day simple moving average is $95.76 and its 200-day simple moving average is $92.57.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last posted its earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02. The company had revenue of $2.06 billion during the quarter, compared to analysts’ expectations of $2.04 billion. Zimmer Biomet had a net margin of 8.95% and a return on equity of 13.02%. Zimmer Biomet’s revenue for the quarter was up 3.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.90 earnings per share. As a group, analysts expect that Zimmer Biomet will post 8.56 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Chad Phipps sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $98.35, for a total value of $295,050.00. Following the transaction, the insider owned 65,231 shares in the company, valued at $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the company’s stock in a transaction on Friday, September 11th. The stock was sold at an average price of $92.95, for a total transaction of $528,978.45. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 1.28% of the company’s stock.

Hedge Funds Weigh In On Zimmer Biomet

Hedge funds have recently modified their holdings of the business. Tacita Capital Inc acquired a new position in Zimmer Biomet during the second quarter worth $26,000. Ancora Advisors LLC acquired a new stake in shares of Zimmer Biomet in the second quarter valued at $29,000. Elevation Wealth Partners LLC grew its stake in shares of Zimmer Biomet by 145.9% in the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after buying an additional 229 shares in the last quarter. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zimmer Biomet in the first quarter valued at $44,000. Finally, Parvin Asset Management LLC purchased a new stake in shares of Zimmer Biomet in the 2nd quarter valued at $47,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

About Zimmer Biomet

(Get Free Report)

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.

See Also

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.